Quest Diagnostics Incorporated (DGX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, DGX scores 78 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are: Fundamental Cash Engine at 16/20 (ROIC 10.3%; FCF yield 4.88%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 14/20 (Beta 1.01; sector sensitivity), and Forensic Balance Sheet at 16/20 (Altman Z 4.01; Piotroski F 8/9; Debt/Equity 0.72).

For a prospective investor, the strongest pillar is institutional flow (18/20), which the rating frames as the main upside driver. The cash engine and balance sheet pillars (both 16/20) indicate a business generating cash with forensic metrics the rating characterizes as sound. The lowest-scoring pillars are insider conviction and macro regime fit (both 14/20), meaning insider signals and macro sensitivity contribute less to the overall score. Valuation is a tradeoff: per the market data, P/E (TTM) is 28.1 and forward P/E is 26.1, which are elevated relative to the FCF yield of 4.88%. The rating's cash-based case therefore depends on continued earnings and cash growth to support the current multiple. This is an analytical summary of the rating, not personalized financial advice.

Per the market data, gross margin is 33.2%, operating margin is 14.1%, and net margin is 9%, with ROIC at 10.3%. Per the Roarable RQD rating, the Altman Z-Score is 4.01, the Piotroski F-Score is 8/9, and Debt/Equity is 0.72. Revenue, operating income, and net income each rose across the three reported periods in the SEC financials. Debt was $5615.0M in FY 2024 and $5167.0M in FY 2025, while cash was $549.0M and $420.0M in those years respectively.

Per the recent news and catalysts section, six items reference DGX. The headlines reference a Q3 earnings release, with one item reporting "Q3 Adjusted EPS $3.00 per Share, vs. FactSet Est of $2.87." One Seeking Alpha item is headlined "Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's" and carries a GREEN light and CATALYST impact label. The remaining items carry YELLOW lights and MARKET WIRE labels. Risk watch items are not separately identified in the source data beyond the general market-wire classification. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What are the specific revenue segments, customer types, and product lines behind the reported revenue figures?
• What were the reported EPS values for FY 2023 through FY 2025, since the SEC financials list EPS as N/A?
• What is the cash balance for FY 2023, which is listed as N/A?
• What are the specific Q3 results and guidance referenced in the news headlines beyond the single adjusted EPS figure?
• What analyst consensus rating and price targets exist, and what are the individual insider and 13F transactions behind the RQD flow pillars?